Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-294,104
Closed -$2.7M 4311
2025
Q1
$2.7M Buy
294,104
+37,149
+14% +$233K ﹤0.01% 3385
2024
Q4
$1.72M Sell
256,955
-1
-0% -$9 ﹤0.01% 3616
2024
Q3
$2.58M Hold
256,956
﹤0.01% 3480
2024
Q2
$4.01M Sell
256,956
-25,885
-9% -$434K ﹤0.01% 3350
2024
Q1
$6.19M Buy
282,841
+4,194
+2% +$93.1K ﹤0.01% 3209
2023
Q4
$5.39M Buy
278,647
+23,882
+9% +$436K ﹤0.01% 3260
2023
Q3
$4.7M Buy
254,765
+15,170
+6% +$273K ﹤0.01% 3276
2023
Q2
$4.42M Buy
239,595
+29,903
+14% +$707K ﹤0.01% 3366
2023
Q1
$6.07M Sell
209,692
-56
-0% -$1.49K ﹤0.01% 3213
2022
Q4
$5.82M Buy
209,748
+70,546
+51% +$2.68M ﹤0.01% 3235
2022
Q3
$7.64M Buy
139,202
+5,563
+4% +$305K ﹤0.01% 3090
2022
Q2
$7.34M Buy
133,639
+7,354
+6% +$271K ﹤0.01% 3163
2022
Q1
$4.68M Sell
126,285
-32,884
-21% -$1.17M ﹤0.01% 3565
2021
Q4
$3.87M Buy
159,169
+56,089
+54% +$1.88M ﹤0.01% 3750
2021
Q3
$4.64M Buy
103,080
+472
+0.5% +$19.8K ﹤0.01% 3710
2021
Q2
$4.79M Sell
102,608
-11,970
-10% -$611K ﹤0.01% 3632
2021
Q1
$6.34M Buy
114,578
+6,315
+6% +$384K ﹤0.01% 3401
2020
Q4
$6.72M Buy
108,263
+5,828
+6% +$357K ﹤0.01% 3200
2020
Q3
$5.99M Buy
102,435
+14,255
+16% +$1.06M ﹤0.01% 3058
2020
Q2
$9.84M Buy
88,180
+1,470
+2% +$105K ﹤0.01% 2780
2020
Q1
$5.84M Buy
86,710
+1,480
+2% +$149K ﹤0.01% 2906
2019
Q4
$11.8M Buy
85,230
+16,809
+25% +$2.18M ﹤0.01% 2779
2019
Q3
$7.18M Buy
68,421
+19,214
+39% +$1.92M ﹤0.01% 2990
2019
Q2
$5.23M Sell
49,207
-14,019
-22% -$1.85M ﹤0.01% 3156
2019
Q1
$9.77M Buy
63,226
+6,359
+11% +$737K ﹤0.01% 2836
2018
Q4
$5.29M Buy
56,867
+4,888
+9% +$698K ﹤0.01% 3069
2018
Q3
$9.69M Buy
51,979
+827
+2% +$236K ﹤0.01% 2936
2018
Q2
$21.5M Buy
51,152
+31,499
+160% +$10.6M ﹤0.01% 2534
2018
Q1
$5.9M Buy
19,653
+2,237
+13% +$620K ﹤0.01% 3075
2017
Q4
$4.94M Buy
+17,416
New +$4.9M ﹤0.01% 3139

Vanguard Group's OPTN Position: Q2 2025 in Review

Vanguard Group sold out of OptiNose (OPTN) in Q2 2025, closing a stake of 294,104 shares — an estimated $2.7M sold.

Vanguard Group first reported a position in OPTN in Q4 2017 and held it in 30 quarters. The position peaked at $21.5M in Q2 2018. 0 funds tracked by Wall St. Rank hold OPTN as of Q2 2025.

  • Vanguard Group reported no remaining OptiNose position as of Q2 2025 after selling out during the quarter.
  • Vanguard Group sold 294,104 OptiNose shares in Q2 2025, an estimated $2.7M.
  • Vanguard Group first reported a position in OptiNose in Q4 2017 and held it in 30 quarters.
  • Vanguard Group's OptiNose position peaked at $21.5M in Q2 2018.
  • 0 funds tracked by Wall St. Rank held OptiNose as of Q2 2025.

Based on Vanguard Group's 13F filing for Q2 2025, filed 11 Aug 2025.